exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies Marco Meglio

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

Open Label Extension Confirms Cenobamate's Efficacy in Asian Populations Louie Pasculli

New data highlights cenobamate's effectiveness in reducing focal seizures in Asian populations, showcasing significant improvements and potential long-term benefits for patients.

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome Marco Meglio

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

NeurologyLive® Brain Games: December 7, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome Isabella Ciccone, MPH

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

NeurologyLive® Friday 5 — December 5, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

Todays Updates

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

5 Pulmonology Headlines You Missed in November 2025

5 Pulmonology Headlines You Missed in November 2025

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Stage 5 CKD May Reverse Female Survival Advantage

Stage 5 CKD May Reverse Female Survival Advantage

Todays Updates

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

5 Pulmonology Headlines You Missed in November 2025

5 Pulmonology Headlines You Missed in November 2025

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Stage 5 CKD May Reverse Female Survival Advantage

Stage 5 CKD May Reverse Female Survival Advantage

Latest News

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

New data highlights cenobamate's effectiveness in reducing focal seizures in Asian populations, showcasing significant improvements and potential long-term benefits for patients.

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

News All Time

Alzheimer Vaccine ABvac40 Results in Lowered Cortical Perfusion Decline Marco Meglio

A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.

CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease Isabella Ciccone, MPH

Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.

Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment Louie Pasculli

The adaptive PRImus-AD phase 2a trial will evaluate the safety and efficacy of PRI-002, a novel investigational agent, in patients with mild cognitive impairment or mild Alzheimer disease.

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

This Week on NeurologyLive® — December 1, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: November 30, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

Expanding Neurology Care in South Miami: Peter Abdelmalik’s Vision Marco Meglio, Peter Abdelmalik, MD

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

Incorporation of Mini-Mental State Exam Z-Scores May Increase Eligibility for Anti-Amyloid Treatments, Study Suggests Marco Meglio

A Korean study reveals that adjusted MMSE thresholds significantly increase eligibility for anti-amyloid treatments, highlighting demographic disparities and safety concerns.

Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug Marco Meglio

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer’s, enhancing treatment options for early-stage patients.

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Recommended News For You

It Is Not Just the Royals Who Go Through Cancer.

Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

Lower screening age calls for more tailored bowel cancer surveillance

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Black and Hispanic children with high-risk neuroblastoma have worse outcomes despite standardized treatment

Recommended Articles For You

The Life-Saving Powers of Anemia: How to Combat the Disease. 

HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management 

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review 

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

2.

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

3.

Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

4.

The pandemic had little impact on mental health symptoms.

5.

Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

1.

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond

2.

AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data

3.

Understanding the Rare Disease: Werner Syndrome Explained 

4.

From Bench to Bedside: The New Era of Lymphoma Treatment and Education

5.

Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

4.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot